That is where we are heading.
You do understand that the stock market is FORWARD LOOKING and will price in events 6 months to 1 year in advance. The stock will not wait for insurance coverage to happen and then rally. It will rally into the insurance coverage and then sell off once this is accomplished one year later. So you have it backwards.
A poster on this message board indicated this possible date of MARCH 20, 2014 for Fed Panel date.
We are on target if correct, then FDA approval and, $ 12 per share.
Look at the chart and it looks like ETRM is getting ready to EXPLODE to new highs.
The trigger: FDA Panel date announcement.
PS: I can't believe CSIQ which I had bought at $ 3.75 last March 2013 is now 9 months later $ 43.70 for a 1200% return to date to investors whom held on. Of course I sold way too early on it. I am looking for 1200% return on ETRM.
Huge Upward moved coming, solid support here at $ 2.50. We will soar through to new HIGHS, expecting announcement any day of Fed Panel.
I am almost certain 100% FDA will APPROVE VBLOC, the data especially at 18th months is too strong and, the safety on this device is simply outstanding. This has been the main worry in diet devices and pills.
VBLOC beats this hands down.
We are still very early in the up phase, once we start and go over $ 5, then it is DOUBLE DIGITS as large institutions will buy.
This slight pullback will enable us to break to new highs. ETRM tendency has been to make new highs, pull back a little and then roar ahead to new highs again. This is the pattern from $ 1.14 to date. I have not sold at all and not interested either as valuation of ETRM of just $ 145 million is too low. This is a value given to companies whom have no products, not one with FDA Approval written all over it selling into a billion dollar obesity market.
Anyways, happy are those who can see this opportunity and capitalize on it by LOADING UP while stock is under the RADAR. Once it is out of the RADAR, it will a non stop rally easily hitting my $ 12 per share target.
It may happen sooner than you expect. ETRM is too cheap compared to competition and a buyout could easily be done without costing big pharma too much. I do believe MEDTRONIC has an eye on ETRM.
Sensa, a Los Angeles area weight-loss company, has been fined $26.5 million by the Federal Trade Commission for deceptive advertising.
Sensa sells a powder for $59 a month that customers are supposed to sprinkle on food to help them feel full faster, thus losing weight. But the FTC isn’t buying those claims.
“The defendants did not have competent and reliable scientific evidence to support these claims,” according to the FTC’s complaint.
The FTC said it originally imposed a $46.5 million judgment on Sensa and its founders, but was accepting a reduced amount “due to their inability to pay.” The company was said to have sales of $364 million between 2008 and 2012. The FTC also charged two other companies, L’Occitane and HCG Diet Direct, and said it reached what it called a partial settlement with a fourth firm called LeanSpa.
In addition to Sensa Products and its parent company Sensa Inc., the complaint also named Sensa CEO Adam Goldenberg as a defendant.
Goldenberg, as many in the e-commerce industry know, was the CEO of Intelligent Beauty, now known as Sensa Inc. The holding company previously incubated DermStore, a beauty product e-commerce site that Target acquired in August.
The third, and perhaps best-known, Goldenberg is associated with is JustFab. JustFab sells women’s shoes on a subscription basis, charging members $39.95 a month. Last year the company acquired a similar Los Angeles startup called ShoeDazzle, and the two companies are expected to bring in $400 million in revenue and hit profitability this year, Goldenberg told me last year.
But JustFab also has some marketing-related issues that customers and media have pointed out over the years related to how it markets and explains its subscription program. In September, for example, TechCrunch published an article pointing out that JustFab’s checkout process in Germany made it much more clear than the one on its U.S. site how to purchase a pair of shoes without signing up for its monthly subscription program.
When I broached this topic with Goldenberg in a visit to JustFab’s office in December, he contended that the TechCrunch article ran as JustFab was rolling out a new checkout page that just hadn’t hit the U.S. site yet and did two weeks later. He also said that JustFab has 1.5 million active monthly subscribers and that it never could have grown so large if its customers thought its practices were shady.
“When you’re this large and have that many customers, a very small percent that don’t understand it well still make a lot of noise,” he told me.
To be clear, JustFab hasn’t been charged with anything. But Goldenberg’s involvement with a company that the FTC just hit with a giant fine for deceptive advertising probably won’t help JustFab’s perception.
Goldenberg did not immediately respond to an email seeking comment.
Absolutely no sane person is going to place a $ 100,000 call bet on May $ 2.50 without having received from some place from reassurances. That is a huge amount of money for a call option.
This tells me the buyer either got wind of something or that news is imminent.
If FDA says no PANEL, we open at $ 5 and up. Might happen as 18th month data was very strong and pills + stomach staples is not working.
Could be BUYOUT in the works too as other firm takes material position via options to approach management without too much fuss from media.
Very bullish, top management approved significant increase in options to purchase shares high personnel, expecting a big rally on pending Fed Panel and FDA approval.
With this and option buyer of $ 100,000 of May 2.50 calls tells me that news is imminent and to expect EXPLOSION in price.
Better Load up, Price Target $12 per share.
Very bullish for someone to plunk down $ 100,000 bet within only 3.5 months.
News must be pending....
Sounds like VBLOC is starting to finally get the respect and attention it deserves, a serious alternative to diet pills and stomach staples.
Only capturing 50,000 patients per year yields earnings of $ 1.67 per share.
I don't if your questions relates to price target or buyout. However I believe we will hit both this year so $ 12 per share is my target price and possible buyout too. Obesity market is a multi billion market per year and so far no one has succeeded not diet pills nor stomach staples so the door is wide open to something in between which is VBLOC.
My son lost 80 pounds on his own by controlling his hunger, something VBLOC does. Not everyone has my son's determination. He is young and can do it, I am too old and would need VBLOC.
If you gave me a choice of diet pills, stomach staple or VBLOC, I would choose VBLOC due to SAFETY which is my biggest concern as I don't have to alter my lifestyle too much and yet go from being obese to say non-obese over time.
I would suggest you LOAD UP before we really begin to RALLY. This is only a small taste of things to come, the best of the cake is forthcoming.
The more due diligence I have done on VBLOC the more confident I become in its approval and, also more confident VBLOC will fill a significant VOID which exists in the market for obesity.
For starters OBESITY in the USA is an epidemic and only getting worse. It costs $ 147 billion per year to treat these people. In terms of people 33% of US is obese meaning 100 million people. Obamacare changed the focus on obesity, from now on insurance have to provide coverage and employers are forced to get employees to seek help or face higher premium costs. The government wants to get obesity to reasonable levels and is working with ETRM to get VBLOC approved.
The government approved diet pills with dangerous side effects to help however the doctors have blocked this adoption not pushing it to patients. Patients are fearful so diet pills are not working.
Patients were given an option with stomach staple. There are 20 million patients whom qualify per year and yet only 300,000 do surgery. The hold back: serious side effects.
People want to lose weight in a reasonable manner, which means no serious diet changes that will be forced by stomach staples or diet pills where you lose weight and die of a heart attack.
This opens the door to VBLOC. It is safe, has diebetic and hypertension benefits. You don't have to alter your life style in terms of eating habits, it is device which controls hunger. You can remove VBLOC any time you want and it is not too invasive in terms of surgery, recovery quickly with lots of hope for weight loss. The long term effects show that even at 30 months patients are maintaining serious weight loss.
In terms of market potential, each device retails for $ 10,000 with $ 10,000 for hospital stay. If VBLOC gets a reason amount of just the stomach staple crowd say 50,000 patients per year, revenues will be $ 500 million and earnings $ 1.67/share.
ETRM will be bought out as market is huge. Double digits soon enough.
I was taking a shower this morning when I was filled with an instinct, can't explain, that there will announcement of FDA Panel date shortly. We will see if this feeling is correct.
Trading price will be $ 3.25 to $ 3.50, new high based on volume of about 20 million shares.
Lets see, it is just an instinct, I could be wrong,
FDA News should be pretty close to announcement as it is almost 180 days from initial filing.
A surprise announcement of no requirement for PANEL would send us up sharply.
Stock was a $ 30 stock on potential in 2009 which is now becoming a reality in 2014 so we have lots of room to RALLY.
There are 300,000 surgeries per year on stomach staple. Most of the 20 million people in USA who are truly obese are not undergoing staple surgery due to risk and fact that they do not really want to change eating habits.
With VBLOC there is no risk and even has benefits of diebetic and hypertension, no change in eating habits required, surgery is not invasive as stomach staple, recovery is so much faster and, you lose weight. Device controls your hunger and not your change in lifestyle which is difficult to do.
With only 25,000 patients, revenue is $250 million and earnings is 83 cents per share.
I dare say we will probably do as work gets out 200,000 to 300,000 surgeries per year so we are talking about 10 times the 25,000 patient volume I gave.
The stock traded at $ 30 per share based on potential but this is soon a reality so we will really RALLY hard non-stop for 6 months once market wakes up to it.
Better LOAD UP or you will really miss the boat and be kicking yourself in 6 months.